Perhexiline
As of the edition of 20 October 2026, Perhexiline is a small molecule: withdrawn from the market in 1985; acts on CPT1B, CPT2 and MTOR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 1985
- Kind
- Small molecule
- Withdrawn from market
- 1 January 1985 (in some regions)
- Registered trials
- 8, 2 stopped early
- Disease areas
- Heart and blood vessels; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 5 | 3 | 0 | 1 |
| Phase 3 | 3 | 1 | 0 | 1 |
| All trials | 8 |